Invasive disease-free survival and gene expression signatures in CALGB (Alliance) 40601, a randomized phase III neoadjuvant trial of dual HER2-targeting with lapatinib added to chemotherapy plus trastuzumab
- Citation:
- Cancer Res vol 78 (4 Supplement) GS3-02
- Meeting Instance:
- SABCS 2017
- Year:
- 2018
- Type:
- Abstract
- Sub type:
- Poster Discussion
- Funding:
- NCTN
- Endpoint:
- Secondary
- Analysis:
- Primary
- Data Sharing:
- No-Data-Sharing
- Status:
- Presented/Published
- Citation Status:
- epub
- Note:
- Methodological:
- No
- Biospecimen:
- No
- SDC:
- No
- Parents:
- None
- Children:
- 3314
- Pharmas:
- Grants:
- U10CA180821, U10CA180882
- Corr. Author:
- Authors:
- Ian E. Krop David Hillman Mei Polley Maki Tanioka Joel S. Parker Lucas Huebner N. Lynn Henry Sara Tolaney Chau Dang Lyndsay Harris Donald A. Berry Charles M. Perou Ann Partridge Lisa A. Carey
- Networks:
- LAPS-CT018, LAPS-MA036, LAPS-NC007, LAPS-NY016, LAPS-UT003
- Study
- CALGB-40601
- Multiple Studies, or Legacy Studies in Alliance Study:
- Phases:
- 3
- Keywords: